This is a working overview of regulatory schedule, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Perineural cysts were first described by Dr. Isadore Tarlov in 1938. While conducting anatomical dissections of 30 human cadavers to study the filum terminale and lower spinal nerve roots, Tarlov identified cystic lesions on the S2 to S5 sacral nerve roots in five specimens, ranging in size from a pinhead to approximately 2 cm. He also reported degenerative changes in the nerve fibers, ganglion cells, and disintegration of myelin sheaths. These observations were published in a paper titled "Perineurial Cysts of the Spinal Nerve Roots (1938)", in which he suggested the possible clinical relevance of the cysts, stating: "One wonders whether they may not be responsible for the discomfort in certain cases of sciatica or nerve root pains, in which any other pathologic basis has been excluded. This awaits further studies with clinical and pathologic correlations." In 1948, Tarlov reported the first clinical case linking sacral perineural cysts to sciatic pain, establishing their potential as a treatable cause of radiculopathy. He described a 42-year-old woman who developed persistent right-sided sciatica following a fall. Although a herniated intervertebral disc was initially diagnosed, surgical exploration revealed a perineural cyst arising from the right S2 sacral nerve root, located under the posterior arch of the sacrum. The lesion was excised along with part of the dorsal root and ganglion. Postoperatively, the patient experienced significant improvement in motor function, pain, and sensation, without complications.
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue. There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms. The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered. The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis. Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease. Treatment is with thyroid hormone replacement. Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.
=== Other oxidation states === Although Pd(IV) compounds are comparatively rare, one example is sodium hexachloropalladate(IV), Na2PdCl6. Pd(II) and Pd(IV) can transform into each other under certain electrochemical conditions. A few compounds of palladium(III) are also known. Palladium(VI) was claimed to have been synthesized in 2002, but subsequently disproven. Mixed valence palladium complexes exist, e.g. Pd4(CO)4(OAc)4Pd(acac)2 forms an infinite Pd chain structure, with alternatively interconnected Pd4(CO)4(OAc)4 and Pd(acac)2 units. When alloyed with a more electropositive element, palladium can acquire a negative charge. Such compounds are known as palladides, such as gallium palladide. Palladides with the stoichiometry RPd3 exist where R is scandium, yttrium, or any of the lanthanides.
Sources: en.wikipedia.org
5β-Pregnane, also known as 17β-ethyletiocholane or as 10β,13β-dimethyl-17β-ethyl-5β-gonane, is a steroid and a parent compound of a variety of steroid derivatives. It is one of the epimers of pregnane, the other being 5α-pregnane. Derivatives of 5β-pregnane include the naturally occurring steroids 5β-dihydroprogesterone, pregnanolone, epipregnanolone, pregnanediol, and pregnanetriol, and the synthetic steroids hydroxydione, renanolone, ORG-20599, and SAGE-217. These derivatives include metabolites of progesterone and endogenous and synthetic neurosteroids. Etiocholane Gonane
Ataxia Severe hypoventilation Acute narrow-angle glaucoma Severe hepatic deficiencies (hepatitis and liver cirrhosis decrease elimination by a factor of two) Severe renal deficiencies (for example, patients on dialysis) Liver disorders Severe sleep apnea Severe depression, particularly when accompanied by suicidal tendencies Psychosis Pregnancy or breastfeeding Caution required in elderly or debilitated patients Coma or shock Abrupt discontinuation of therapy Acute intoxication with alcohol, narcotics, or other psychoactive substances (with the exception of hallucinogens or some stimulants, where it is occasionally used as a treatment for overdose) History of alcohol or drug dependence Myasthenia gravis, an autoimmune disorder causing marked fatiguability Hypersensitivity or allergy to any drug in the benzodiazepine class
== Academic career == Following his Ph.D. degree research into the pharmacokinetics of amphetamines, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967–75). While at UCSF. Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one, including the clearance concept that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973) (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007. In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties. In 1983 he founded Medeval, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996). He has promoted the application of microdosing in clinical drug development.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.